CSL (OTCMKTS:CSLLY) Shares Gap Up – Time to Buy?

Shares of CSL Limited Sponsored ADR (OTCMKTS:CSLLY) gapped up prior to trading on Wednesday. The stock had previously closed at $32.17, but opened at $33.60. CSL shares last traded at $32.2450, with a volume of 874 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on CSLLY shares. Royal Bank Of Canada upgraded CSL from a “hold” rating to a “moderate buy” rating in a research note on Tuesday, September 15th. Zacks Research upgraded CSL from a “strong sell” rating to a “hold” rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.

CSL Trading Up 1.0%

The business’s 50-day simple moving average is $30.19 and its two-hundred day simple moving average is $24.15. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.21 and a quick ratio of 0.97.

CSL Company Profile

CSL Limited is an Australia-based biopharmaceutical company that develops and manufactures medicines, vaccines and other healthcare products. The company serves patients, healthcare providers and public health systems worldwide through its major businesses, CSL Behring, CSL Seqirus and CSL Vifor.

CSL Behring specializes in plasma-derived and recombinant therapies for immune deficiencies, bleeding disorders, hereditary angioedema and other rare or serious conditions. CSL Seqirus develops and supplies influenza vaccines and other vaccines, while CSL Vifor focuses on treatments for iron deficiency, kidney disease and related conditions.

The company traces its origins to Commonwealth Serum Laboratories, which was established by the Australian government in 1916.